the Rubicon Project, Inc. (NYSE:RUBI) shares decreased -2.24% in last trading session and ended the day at $15.70. RUBI Gross Margin is 77.90% and its has a return on assets of -5.10%. the Rubicon Project, Inc. (NYSE:RUBI) quarterly performance is 2.95%.
The Rubicon Project Inc , (NYSE:RUBI) a company that focuses on automating the buying and selling of advertising, announced a new partnership on Tuesday with Zynga Inc. Rubicon stated in a press release that the agreement offers marketers for the first time ever access to Zynga’s premium guaranteed and reserved inventory via programmatic buying.
The Brink’s Company (NYSE:BCO) ended the last trading day at $28.34. Company weekly volatility is calculated as 2.60% and price to cash ratio as 7.87. The Brink’s Company (NYSE:BCO) showed a weekly performance of -4.06%.
On 4 January, Brink’s Company (NYSE:BCO) announced it has reached an agreement with activist investor and shareholder Starboard Value. As part of the agreement, Brink’s announced the addition of three new independent directors to the company’s Board of Directors and its current CEO, Thomas Schievelbein, will retire.
On 06 January, Ampco-Pittsburgh Corp. (NYSE:AP) shares decreased -1.95% and was closed at $10.08. AP EPS growth in last 5 year was -15.30%. Ampco-Pittsburgh Corp. (NYSE:AP) year to date (YTD) performance is -1.75%.
Ampco-Pittsburgh Corporation (NYSE:AP) announced the declaration of a quarterly dividend of eighteen cents ($.18) per share on the common stock of the Corporation. The dividend will be paid on January 29, 2016 to shareholders of record on January 15, 2016.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares decreased -2.34% in last trading session and ended the day at $36.72. SRPT has a return on assets of -83.80%. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) quarterly performance is -3.37%.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review Sarepta’s New Drug Application (NDA) for eteplirsen, on January 22, 2016. The Prescription Drug User Fee Act (PDUFA) action date for completion of FDA review of the eteplirsen NDA is February 26, 2016.
Euro Tech Holdings Company Limited (NASDAQ:CLWT) caters to the Industrial Goods space. It has a net profit margin of 1.10% and weekly performance is -5.23%. On the last day of trading company shares ended up at $2.72. Euro Tech Holdings Company Limited (NASDAQ:CLWT) distance from 50-day simple moving average (SMA50) is 5.54%.
On 23 December, Euro Tech Holdings Company Limited (NASDAQ:CLWT) reported its unaudited financial results for the six months ended June 30, 2015. The Company’s revenues for the six months ended June 30, 2015 (“1H 2015”) were approximately US$8,273,000, a 16.1% decrease as compared to approximately US$9,863,000 for the six months ended June 30, 2014 (“1H 2014”). This decrease was primarily attributable to the decrease in revenues from engineering activities under the current poor economic conditions.
Leave a Reply